Prenetics Global Limited

PRENW ·Healthcare, Drug Manufacturers - General, Hong Kong
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2024 FY2023 FY2022 FY2021 FY2020
Operating Activities
Net Income $-46.3M $-62.7M $-190.5M $-174.0M $-1.9M
Depreciation & Amortization — — — — —
Depreciation $2.0M $3.0M $1.1M $938.0K $708.6K
Amortization — — — — —
Stock-Based Compensation $7.4M $10.5M $25.9M $20.4M $1.2M
Net Cash from Operating Activities $-28.9M $-13.8M $14.5M $13.4M $-2.9M
Investing Activities
Capital Expenditures $1.0M $345.0K $4.9M $8.5M $2.9M
Business Acquisitions — — — — —
Net Cash from Investing Activities $38.5M $-83.0M $-46.1M $-22.0M $-6.0M
Financing Activities
Dividends Paid — — — — —
Stock Repurchases — — — — —
Net Cash from Financing Activities $-3.3M $-4.7M $143.3M $29.3M $11.8M
Net Change in Cash — — — — —
Free Cash Flow $-29.9M $-14.1M $9.6M $4.9M $-5.7M